This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2016
  • /
  • 05
  • /
  • UK NICE issues positive recommendation for Zykadia...
Drug news

UK NICE issues positive recommendation for Zykadia (ceritinib) to treat ALK+ non small cell lung cancer- Novartis

Read time: 1 mins
Last updated:24th May 2016
Published:24th May 2016
Source: Pharmawand

UK's NICE has announced that Zykadia (ceritinib), from Novartis, has been recommended in line with its marketing authorisation, for the treatment of advanced ALK-positive non small cell lung cancer (NSCLC) in adults who have previously been treated with Pfizer's Xalkori (crizotinib). The regulator's decision is dependent on the continued provision of a patient access scheme, in which Novartis contnues to offer the drug to the NHS at a discounted price to ensure value for money. This is in contrast to the decision announced by NICE in November 2015.

Comment: Ceritinib is structurally distinct from crizotinib and has a 20-fold greater potency against the target than its more advanced rival, making it a prime candidate for use in resistant patients. Despite high initial responses to Xalkori therapy, patients usually acquire resistance to the drug and relapse within a year. Resistance mechanisms involved include ALK gene mutation, ALK gene amplification or activation of other tyrosine kinases such as EFGR. Approximately 2-7% of patients with NSCLC harbour the ALK gene rearrangement, which causes cancer growth.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.